HTG Molecular Diagnostics
HTGM
HTGM was delisted on the 14th of June, 2023.
54 hedge funds and large institutions have $67M invested in HTG Molecular Diagnostics in 2018 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 9 closing their positions.
1,933% more call options, than puts
Call options by funds: $61K | Put options by funds: $3K
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
23% more funds holding
Funds holding: 44 → 54 (+10)
2.57% less ownership
Funds ownership: 49.25% → 46.69% (-2.6%)
28% less capital inflows, than outflows
Capital inflows: $5.98M | Capital outflows: $8.31M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$791K |
| 2 |
Timpani Capital Management
Milwaukee,
Wisconsin
|
+$756K |
| 3 |
Granite Point Capital Management
Boston,
Massachusetts
|
+$733K |
| 4 |
Millrace Asset Group
Berwyn,
Pennsylvania
|
+$733K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$367K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stonepine Capital Management
Bend,
Oregon
|
-$4.23M |
| 2 |
Putnam Investments
Boston,
Massachusetts
|
-$1.23M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$978K |
| 4 |
Spark Investment Management
New York
|
-$663K |
| 5 |
GSA Capital Partners
London,
United Kingdom
|
-$529K |
HTGM Hedge Fund Activity: Q3 2018 in Review
54 of the 4,393 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics (HTGM) for Q3 2018, worth a combined $67M — up 47% from $45.6M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new HTGM positions and 9 closed out — a net gain of 10 holders — while 14 added to existing stakes and 11 trimmed.
The largest buyer was Russell Investments Group, opening a new position worth an estimated $791K. The largest seller was Stonepine Capital Management, cutting an estimated $4.23M.
- 54 institutional investors held HTG Molecular Diagnostics (HTGM) as of Q3 2018, up from 44 in Q2 2018.
- Funds reported $67M of HTG Molecular Diagnostics stock for Q3 2018, up 47% quarter-over-quarter.
- 19 funds opened new HTG Molecular Diagnostics positions in Q3 2018 and 9 closed out, a net change of +10 holders.
- The largest HTG Molecular Diagnostics buyer in Q3 2018 was Russell Investments Group, an estimated $791K added.
- The largest HTG Molecular Diagnostics seller in Q3 2018 was Stonepine Capital Management, an estimated $4.23M sold.
Based on aggregated 13F filings for Q3 2018.